Autres langues Viridian Therapeutics, Inc.

Actions

VRDN

US92790C1045

Temps réel estimé Cboe BZX Autres places de cotation 20:15:34 03/05/2024			Varia. 5j.	Varia. 1 janv.
15,45 ^USD	+5,97 %		+19,88 %	-29,11 %

21/03	VIRIDIAN THERAPEUTICS, INC. : B. Riley réitère son opinion positive sur le titre	ZM
28/02	VIRIDIAN THERAPEUTICS, INC. : Wedbush persiste à l'achat	ZM

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	14:02
Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024	29/04
Foghorn Therapeutics Names Kristian Humer CFO	16/04
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	04/04
VIRIDIAN Kaskela Law LLC Announces Investigation of Viridian Therapeutics, Inc. (VRDN) and Encourages Investors to Contact the Firm	29/03
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	06/03
Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference	05/03
Viridian Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/02
Viridian Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	27/02
Earnings Flash (VRDN) VIRIDIAN THERAPEUTICS Posts Q4 Revenue $72,000	27/02
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results	27/02
Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer	19/02
Viridian Therapeutics Names Jennifer Tousignant as Chief Legal Officer	16/02
Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer	16/02
Viridian Therapeutics, Inc. Appoints Jennifer Tousignant as Chief Legal Officer	16/02
Viridian Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(4)	07/02
Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	06/02
Viridian Therapeutics Prices Common Stock Offering at $21 per Share	18/01
Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock	18/01
Viridian Therapeutics Starts Underwritten Stock Offering; Shares Fall After Hours	17/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Viridian Therapeutics, Inc.

Actions

VRDN

US92790C1045

Autres langues

Filtres